X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (214) 214
Publication (30) 30
Patent (24) 24
Book / eBook (7) 7
Book Chapter (3) 3
Book Review (2) 2
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (125) 125
rheumatology (94) 94
female (87) 87
male (79) 79
index medicus (77) 77
middle aged (77) 77
systemic sclerosis (73) 73
scleroderma (72) 72
adult (63) 63
aged (41) 41
scleroderma, systemic - complications (33) 33
disease (28) 28
systemic scleroderma (28) 28
mortality (22) 22
autoantibodies (20) 20
classification (19) 19
systemic lupus erythematosus (19) 19
abridged index medicus (18) 18
klinikai orvostudományok (18) 18
orvostudományok (18) 18
patients (18) 18
rheumatoid arthritis (18) 18
risk factors (18) 18
scleroderma, systemic - physiopathology (18) 18
severity of illness index (18) 18
analysis (17) 17
arthritis (17) 17
clinical medicine (17) 17
prognosis (17) 17
scleroderma, systemic - immunology (17) 17
scleroderma, systemic - pathology (17) 17
skin (17) 17
disease progression (16) 16
eular scleroderma trials (16) 16
studies (16) 16
survival (16) 16
clinical trials (15) 15
scleroderma, systemic - diagnosis (15) 15
antibodies (14) 14
case-control studies (14) 14
follow-up studies (14) 14
immunology (14) 14
involvement (14) 14
autoantibodies - blood (13) 13
autoimmune diseases (13) 13
autoimmunity (13) 13
europe (13) 13
fibrosis (13) 13
prospective studies (13) 13
research (13) 13
time factors (13) 13
association (12) 12
health-assessment questionnaire (12) 12
hungary (12) 12
lupus (12) 12
prevalence (12) 12
reumatologi och inflammation (12) 12
rheumatology and autoimmunity (12) 12
scleroderma, systemic - blood (12) 12
treatment outcome (12) 12
validation (12) 12
adolescent (11) 11
care and treatment (11) 11
diagnosis (11) 11
klinisk medicin (11) 11
medical and health sciences (11) 11
medicin och hälsovetenskap (11) 11
medicine & public health (11) 11
performing operations (11) 11
transporting (11) 11
cohort (10) 10
combination or multi-purpose tools not otherwise providedfor (10) 10
databases, factual (10) 10
details or components of portable power-driven tools notparticularly related to the operations performed and nototherwise provided for (10) 10
hand tools (10) 10
manipulators (10) 10
portable power-driven tools (10) 10
retrospective studies (10) 10
scleroderma, systemic - mortality (10) 10
biochemistry (9) 9
biomarkers - blood (9) 9
clinical-trials (9) 9
data bases (9) 9
epidemiology (9) 9
hypertension (9) 9
immunoglobulins (9) 9
medical research (9) 9
metaanalysis (9) 9
microbiology (9) 9
physiological aspects (9) 9
proteins (9) 9
quality of life (9) 9
research article (9) 9
skin and connective tissue diseases (9) 9
animals (8) 8
autoantibodies - immunology (8) 8
death (8) 8
disease-activity (8) 8
measuring (8) 8
medicine (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1968, Occasional papers of the Research Project on National Income in East Central Europe, Volume OP-16, [2], iii, 110
Book
Multiple Sclerosis Journal, ISSN 1352-4585, 8/2016, Volume 22, Issue 9, pp. 1192 - 1201
Background: Neuromyelitis optica (NMO)–systemic lupus erythematosus (SLE) association is a rare condition characterized by multiple autoantibodies. Objective:... 
IL-17 | AQP4 | IP-10 | myelin oligodendrocyte glycoprotein | Th1 | SLE | Th17 | Recurrence | Neuromyelitis Optica - drug therapy | Immunoglobulin G - blood | Autoantibodies - blood | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Lupus Erythematosus, Systemic - blood | Neuromyelitis Optica - immunology | Th1 Cells - immunology | Th1 Cells - metabolism | Young Adult | Th17 Cells - metabolism | Time Factors | Lupus Erythematosus, Systemic - drug therapy | Lupus Erythematosus, Systemic - immunology | Preliminary Data | Adult | Female | Retrospective Studies | Child | B-Lymphocytes - metabolism | Cytokines - blood | Neuromyelitis Optica - diagnosis | Aquaporin 4 - immunology | Lymphocyte Activation | Treatment Outcome | Biomarkers - blood | Neuromyelitis Optica - blood | Remission Induction | Lupus Erythematosus, Systemic - diagnosis | B-Lymphocytes - immunology | Immunoglobulin M - blood | Adolescent | Th17 Cells - immunology | Aquaporin 4 | Immunoglobulin M | Lupus | Immunoglobulins | Oligodendrocyte-myelin glycoprotein | Autoantibodies | Immunoglobulin G | Antibodies | T cell receptors | Lymphocytes T | Cell activation | Systemic lupus erythematosus | Neuromyelitis | Lymphocytes B | Anti-DNA antibodies | Remission | IP-10 protein | CCL17 protein | Chemokines | Neurologi | Medical and Health Sciences | Medicin och hälsovetenskap | Reumatologi och inflammation | Klinisk medicin | Rheumatology and Autoimmunity | Clinical Medicine | Neurology
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 11/2013, Volume 72, Issue 11, pp. 1747 - 1755
Journal Article
1965, Occasional papers of the Research Project on National Income in East Central Europe, Volume OP-8, v, 15
Book
Annals of the Rheumatic Diseases, ISSN 0003-4967, 08/2017, Volume 76, Issue 8, pp. 1327 - 1339
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new... 
Systemic Sclerosis | Cyclophosphamide | Treatment | Methotrexate | ORAL PROSTACYCLIN ANALOG | SCLERODERMA RENAL CRISIS | DIGITAL ULCERS | DOUBLE-BLIND TRIAL | PULMONARY ARTERIAL-HYPERTENSION | INTESTINAL BACTERIAL OVERGROWTH | INTRAVENOUS EPOPROSTENOL | RAYNAUDS-PHENOMENON SECONDARY | STANDARDIZED OPERATING PROCEDURES | RHEUMATOLOGY | STEM-CELL TRANSPLANTATION | Glucocorticoids - therapeutic use | Pyrazoles - therapeutic use | Humans | Gastrointestinal Diseases - etiology | Lung Diseases - therapy | Raynaud Disease - etiology | Hypertension, Pulmonary - therapy | Lung Diseases - etiology | Scleroderma, Systemic - therapy | Delphi Technique | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Raynaud Disease - therapy | Fingers | Scleroderma, Systemic - complications | Phosphodiesterase 5 Inhibitors - therapeutic use | Fluoxetine - therapeutic use | Ulcer - etiology | Ulcer - therapy | Europe | Rheumatology | Serotonin Uptake Inhibitors - therapeutic use | Hematopoietic Stem Cell Transplantation | Gastrointestinal Diseases - therapy | Prostaglandins I - therapeutic use | Pyrimidines - therapeutic use | Kidney Diseases - therapy | Kidney Diseases - etiology | Endothelin Receptor Antagonists - therapeutic use | Hypertension, Pulmonary - etiology | Endothelin | Experts | Fluoxetine | Lung diseases | Clinical trials | Stem cell transplantation | Transplantation | Prostacyclin | Patients | Literature reviews | Studies | Systemic sclerosis | Ulcers | Skin diseases | Scleroderma | Phosphodiesterase | Kidney transplantation | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Reumatologi och inflammation
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 5/2014, Volume 15, Issue S1, pp. S73 - S82
Journal Article
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 5/2014, Volume 15, Issue S1, pp. S53 - S64
Objective The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of... 
Databases | Rheumatoid arthritis | Rheumatology | Placebos | Clinical trials | Experimentation | Arthritis | Operating rooms | Subcutaneous injections | Randomized controlled trials | Rheumatoid | Economic Policy | Public Health | Statistics for Life Sciences, Medicine, Health Sciences | Health Informatics | I10 | Meta-analysis | I19 | Mixed treatment comparison | Medicine & Public Health | Statistics for Business/Economics/Mathematical Finance/Insurance | Biosimilar pharmaceuticals | Public Finance & Economics | ALPHA MONOCLONAL-ANTIBODY | MODIFYING ANTIRHEUMATIC DRUGS | INADEQUATE RESPONSE | PHASE-III | RECEIVING CONCOMITANT METHOTREXATE | ADALIMUMAB PLUS METHOTREXATE | EVERY 4 WEEKS | ANTITUMOR NECROSIS FACTOR | DOUBLE-BLIND | HEALTH POLICY & SERVICES | ECONOMICS | INTERLEUKIN-6 RECEPTOR INHIBITION | Biosimilar Pharmaceuticals - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Biosimilar Pharmaceuticals - adverse effects | Randomized Controlled Trials as Topic | Biological Factors - therapeutic use | Infliximab | Arthritis, Rheumatoid - drug therapy | Antirheumatic Agents - adverse effects | Biological Factors - adverse effects | Antirheumatic Agents - therapeutic use | Rheumatoid factor | Comparative analysis | Drug therapy | Studies | Health economics | Biological products | Economic theory | Economic statistics | Pharmaceuticals | Original Paper
Journal Article
Rheumatology, ISSN 1462-0324, 03/2018, Volume 57, Issue 3, pp. 441 - 450
Journal Article